Ranbaxy's generic Lipitor buoys Daiichi Sankyo against olmesartan weakness
This article was originally published in Scrip
Executive Summary
Daiichi Sankyo's branded-plus-generics "hybrid" business model finally appears to be paying concrete dividends, with Ranbaxy's surging sales of generic atorvastatin offsetting global weakness for the group's top branded product Benicar/Olmetec (olmesartan) in the first quarter.